

Developmental and Epileptic Encephalopathies (DEE) Market, Global Outlook and Forecast 2022-2028

https://marketpublishers.com/r/D5A63309EDA3EN.html

Date: January 2022 Pages: 66 Price: US\$ 3,250.00 (Single User License) ID: D5A63309EDA3EN

Abstracts

Developmental and Epileptic Encephalopathies (DEE) consists of several types of severe brain disorders in which the epileptic electrical discharges may add to progressive psychomotor dysfunction. They are a group of nosologies that are related to an early age and manifest with electroencephalography (EEG) paroxysmal activity that is often aggressive, seizures that are commonly multi-form and intractable, cognitive, behavioral and neurological deficits that may be relentless and sometimes lead to early death. Cognitive deficits and behavioral disturbances are presumed to be the main and sometimes the first and unique manifestation of electrographic epileptic discharges in epileptic encephalopathy. There are various sub syndromes in Epileptic encephalopathies namely West syndrome, Dravet syndrome, Ohtahara syndrome, Lennox-gastaut, Landau-Kleffner syndrome, Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep, Myoclonic Status in Non-Progressive Encephalopathies, Atypical Benign Partial Epilepsy of Childhood, Hypothalamic (Gelastic) Epilepsy.

This report contains market size and forecasts of Developmental and Epileptic Encephalopathies (DEE) in Global, including the following market information:

Global Developmental and Epileptic Encephalopathies (DEE) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Developmental and Epileptic Encephalopathies (DEE) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.



The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Atypical Benign Partial Epilepsy of Childhood Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Developmental and Epileptic Encephalopathies (DEE) include Biocodex, Bio-Pharm Solutions, Eisai Pharmaceuticals, GlaxoSmithKline, Greenwich Biosciences, Janssen Pharmaceuticals, Lundbeck, Mylan Pharmaceuticals and PTC Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Developmental and Epileptic Encephalopathies (DEE) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Developmental and Epileptic Encephalopathies (DEE) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Developmental and Epileptic Encephalopathies (DEE) Market Segment Percentages, by Type, 2021 (%)

Atypical Benign Partial Epilepsy of Childhood

Dravet Syndrome

Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep

Hypothalamic Epilepsy

Landau-Kleffner Syndrome (LKS)

Lennox-Gastaut Syndrome

Myoclonic Status in Non-Progressive Encephalopathies



West Syndrome

Global Developmental and Epileptic Encephalopathies (DEE) Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Developmental and Epileptic Encephalopathies (DEE) Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Developmental and Epileptic Encephalopathies (DEE) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Developmental and Epileptic Encephalopathies (DEE) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.



Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia



UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Developmental and Epileptic Encephalopathies (DEE) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Developmental and Epileptic Encephalopathies (DEE) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Biocodex

Bio-Pharm Solutions

Eisai Pharmaceuticals

GlaxoSmithKline

Greenwich Biosciences

Janssen Pharmaceuticals

Lundbeck

Mylan Pharmaceuticals

PTC Therapeutics

Roche

Takeda Pharmaceutical



Zogenix

Zynerba Pharma

Ovid Therapeutics



Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Developmental and Epileptic Encephalopathies (DEE) Market Definition
- 1.2 Market Segments
- 1.2.1 Market by Type
- 1.2.2 Market by Application
- 1.3 Global Developmental and Epileptic Encephalopathies (DEE) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
- 1.5.1 Research Methodology
- 1.5.2 Research Process
- 1.5.3 Base Year
- 1.5.4 Report Assumptions & Caveats

2 GLOBAL DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE) OVERALL MARKET SIZE

2.1 Global Developmental and Epileptic Encephalopathies (DEE) Market Size: 2021 VS 2028

2.2 Global Developmental and Epileptic Encephalopathies (DEE) Market Size,

Prospects & Forecasts: 2017-2028

2.3 Key Market Trends, Opportunity, Drivers and Restraints

- 2.3.1 Market Opportunities & Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Developmental and Epileptic Encephalopathies (DEE) Players in Global Market3.2 Top Global Developmental and Epileptic Encephalopathies (DEE) Companies

Ranked by Revenue

3.3 Global Developmental and Epileptic Encephalopathies (DEE) Revenue by Companies

3.4 Top 3 and Top 5 Developmental and Epileptic Encephalopathies (DEE) Companies in Global Market, by Revenue in 2021

3.5 Global Companies Developmental and Epileptic Encephalopathies (DEE) Product Type



3.6 Tier 1, Tier 2 and Tier 3 Developmental and Epileptic Encephalopathies (DEE) Players in Global Market

3.6.1 List of Global Tier 1 Developmental and Epileptic Encephalopathies (DEE) Companies

3.6.2 List of Global Tier 2 and Tier 3 Developmental and Epileptic Encephalopathies (DEE) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Developmental and Epileptic Encephalopathies (DEE) Market Size Markets, 2021 & 2028

- 4.1.2 Atypical Benign Partial Epilepsy of Childhood
- 4.1.3 Dravet Syndrome
- 4.1.4 Epilepsy with Continuous Spike-and -Waves during Slow-Wave Sleep
- 4.1.5 Hypothalamic Epilepsy
- 4.1.6 Landau-Kleffner Syndrome (LKS)
- 4.1.7 Lennox-Gastaut Syndrome
- 4.1.8 Myoclonic Status in Non-Progressive Encephalopathies
- 4.1.9 West Syndrome

4.2 By Type - Global Developmental and Epileptic Encephalopathies (DEE) Revenue & Forecasts

4.2.1 By Type - Global Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2022

4.2.2 By Type - Global Developmental and Epileptic Encephalopathies (DEE) Revenue, 2023-2028

4.2.3 By Type - Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Developmental and Epileptic Encephalopathies (DEE) Market Size, 2021 & 2028

5.1.2 Hospital

- 5.1.3 Clinic
- 5.1.4 Others

5.2 By Application - Global Developmental and Epileptic Encephalopathies (DEE) Revenue & Forecasts



5.2.1 By Application - Global Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2022

5.2.2 By Application - Global Developmental and Epileptic Encephalopathies (DEE) Revenue, 2023-2028

5.2.3 By Application - Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Developmental and Epileptic Encephalopathies (DEE) Market Size, 2021 & 2028

6.2 By Region - Global Developmental and Epileptic Encephalopathies (DEE) Revenue & Forecasts

6.2.1 By Region - Global Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2022

6.2.2 By Region - Global Developmental and Epileptic Encephalopathies (DEE) Revenue, 2023-2028

6.2.3 By Region - Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2028

6.3.2 US Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.3.3 Canada Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.3.4 Mexico Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2028

6.4.2 Germany Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.4.3 France Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.4.4 U.K. Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.4.5 Italy Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028



6.4.6 Russia Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.4.7 Nordic Countries Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.4.8 Benelux Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2028

6.5.2 China Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.5.3 Japan Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.5.4 South Korea Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.5.5 Southeast Asia Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.5.6 India Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2028

6.6.2 Brazil Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.6.3 Argentina Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2028

6.7.2 Turkey Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.7.3 Israel Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.7.4 Saudi Arabia Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

6.7.5 UAE Developmental and Epileptic Encephalopathies (DEE) Market Size, 2017-2028

7 PLAYERS PROFILES

Developmental and Epileptic Encephalopathies (DEE) Market, Global Outlook and Forecast 2022-2028



7.1 Biocodex

7.1.1 Biocodex Corporate Summary

7.1.2 Biocodex Business Overview

7.1.3 Biocodex Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.1.4 Biocodex Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.1.5 Biocodex Key News

7.2 Bio-Pharm Solutions

7.2.1 Bio-Pharm Solutions Corporate Summary

7.2.2 Bio-Pharm Solutions Business Overview

7.2.3 Bio-Pharm Solutions Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.2.4 Bio-Pharm Solutions Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.2.5 Bio-Pharm Solutions Key News

7.3 Eisai Pharmaceuticals

7.3.1 Eisai Pharmaceuticals Corporate Summary

7.3.2 Eisai Pharmaceuticals Business Overview

7.3.3 Eisai Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.3.4 Eisai Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.3.5 Eisai Pharmaceuticals Key News

7.4 GlaxoSmithKline

7.4.1 GlaxoSmithKline Corporate Summary

7.4.2 GlaxoSmithKline Business Overview

7.4.3 GlaxoSmithKline Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.4.4 GlaxoSmithKline Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.4.5 GlaxoSmithKline Key News

7.5 Greenwich Biosciences

7.5.1 Greenwich Biosciences Corporate Summary

7.5.2 Greenwich Biosciences Business Overview

7.5.3 Greenwich Biosciences Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.5.4 Greenwich Biosciences Developmental and Epileptic Encephalopathies (DEE)



Revenue in Global Market (2017-2022)

7.5.5 Greenwich Biosciences Key News

7.6 Janssen Pharmaceuticals

7.6.1 Janssen Pharmaceuticals Corporate Summary

7.6.2 Janssen Pharmaceuticals Business Overview

7.6.3 Janssen Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.6.4 Janssen Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.6.5 Janssen Pharmaceuticals Key News

7.7 Lundbeck

7.7.1 Lundbeck Corporate Summary

7.7.2 Lundbeck Business Overview

7.7.3 Lundbeck Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.7.4 Lundbeck Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.7.5 Lundbeck Key News

7.8 Mylan Pharmaceuticals

7.8.1 Mylan Pharmaceuticals Corporate Summary

7.8.2 Mylan Pharmaceuticals Business Overview

7.8.3 Mylan Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.8.4 Mylan Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.8.5 Mylan Pharmaceuticals Key News

7.9 PTC Therapeutics

7.9.1 PTC Therapeutics Corporate Summary

7.9.2 PTC Therapeutics Business Overview

7.9.3 PTC Therapeutics Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.9.4 PTC Therapeutics Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.9.5 PTC Therapeutics Key News

7.10 Roche

7.10.1 Roche Corporate Summary

7.10.2 Roche Business Overview

7.10.3 Roche Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings



7.10.4 Roche Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.10.5 Roche Key News

7.11 Takeda Pharmaceutical

7.11.1 Takeda Pharmaceutical Corporate Summary

7.11.2 Takeda Pharmaceutical Business Overview

7.11.3 Takeda Pharmaceutical Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.11.4 Takeda Pharmaceutical Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.11.5 Takeda Pharmaceutical Key News

7.12 Zogenix

7.12.1 Zogenix Corporate Summary

7.12.2 Zogenix Business Overview

7.12.3 Zogenix Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.12.4 Zogenix Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.12.5 Zogenix Key News

7.13 Zynerba Pharma

7.13.1 Zynerba Pharma Corporate Summary

7.13.2 Zynerba Pharma Business Overview

7.13.3 Zynerba Pharma Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.13.4 Zynerba Pharma Developmental and Epileptic Encephalopathies (DEE)

Revenue in Global Market (2017-2022)

7.13.5 Zynerba Pharma Key News

7.14 Ovid Therapeutics

7.14.1 Ovid Therapeutics Corporate Summary

7.14.2 Ovid Therapeutics Business Overview

7.14.3 Ovid Therapeutics Developmental and Epileptic Encephalopathies (DEE) Major Product Offerings

7.14.4 Ovid Therapeutics Developmental and Epileptic Encephalopathies (DEE) Revenue in Global Market (2017-2022)

7.14.5 Ovid Therapeutics Key News

8 CONCLUSION

9 APPENDIX

Developmental and Epileptic Encephalopathies (DEE) Market, Global Outlook and Forecast 2022-2028



9.1 Note

9.2 Examples of Clients

9.3 Disclaimer



List Of Tables

LIST OF TABLES

Table 1. Developmental and Epileptic Encephalopathies (DEE) Market Opportunities & Trends in Global Market

Table 2. Developmental and Epileptic Encephalopathies (DEE) Market Drivers in Global Market

Table 3. Developmental and Epileptic Encephalopathies (DEE) Market Restraints in Global Market

Table 4. Key Players of Developmental and Epileptic Encephalopathies (DEE) in Global Market

Table 5. Top Developmental and Epileptic Encephalopathies (DEE) Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Developmental and Epileptic Encephalopathies (DEE) Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Developmental and Epileptic Encephalopathies (DEE) Revenue Share by Companies, 2017-2022

Table 8. Global Companies Developmental and Epileptic Encephalopathies (DEE) Product Type

Table 9. List of Global Tier 1 Developmental and Epileptic Encephalopathies (DEE) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Developmental and Epileptic

Encephalopathies (DEE) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Developmental and Epileptic Encephalopathies (DEE) Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Developmental and Epileptic Encephalopathies (DEE) Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Developmental and Epileptic Encephalopathies (DEE) Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Developmental and Epileptic Encephalopathies (DEE) Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Developmental and Epileptic Encephalopathies (DEE)



Revenue (US\$, Mn), 2017-2022 Table 19. By Region - Global Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), 2023-2028 Table 20. By Country - North America Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2022 Table 21. By Country - North America Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2023-2028 Table 22. By Country - Europe Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2022 Table 23. By Country - Europe Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2023-2028 Table 24. By Region - Asia Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2022 Table 25. By Region - Asia Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2023-2028 Table 26. By Country - South America Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2022 Table 27. By Country - South America Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2023-2028 Table 28. By Country - Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2022 Table 29. By Country - Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2023-2028 Table 30. Biocodex Corporate Summary Table 31. Biocodex Developmental and Epileptic Encephalopathies (DEE) Product Offerings Table 32. Biocodex Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022) Table 33. Bio-Pharm Solutions Corporate Summary Table 34. Bio-Pharm Solutions Developmental and Epileptic Encephalopathies (DEE) **Product Offerings** Table 35. Bio-Pharm Solutions Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022) Table 36. Eisai Pharmaceuticals Corporate Summary Table 37. Eisai Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) **Product Offerings** Table 38. Eisai Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022) Table 39. GlaxoSmithKline Corporate Summary



Table 40. GlaxoSmithKline Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 41. GlaxoSmithKline Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 42. Greenwich Biosciences Corporate Summary

Table 43. Greenwich Biosciences Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 44. Greenwich Biosciences Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 45. Janssen Pharmaceuticals Corporate Summary

Table 46. Janssen Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 47. Janssen Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 48. Lundbeck Corporate Summary

Table 49. Lundbeck Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 50. Lundbeck Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 51. Mylan Pharmaceuticals Corporate Summary

Table 52. Mylan Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 53. Mylan Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 54. PTC Therapeutics Corporate Summary

Table 55. PTC Therapeutics Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 56. PTC Therapeutics Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 57. Roche Corporate Summary

Table 58. Roche Developmental and Epileptic Encephalopathies (DEE) ProductOfferings

Table 59. Roche Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 60. Takeda Pharmaceutical Corporate Summary

Table 61. Takeda Pharmaceutical Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 62. Takeda Pharmaceutical Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)



Table 63. Zogenix Corporate Summary

Table 64. Zogenix Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 65. Zogenix Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

Table 66. Zynerba Pharma Corporate Summary

Table 67. Zynerba Pharma Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 68. Zynerba Pharma Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)

 Table 69. Ovid Therapeutics Corporate Summary

Table 70. Ovid Therapeutics Developmental and Epileptic Encephalopathies (DEE) Product Offerings

Table 71. Ovid Therapeutics Developmental and Epileptic Encephalopathies (DEE) Revenue (US\$, Mn), (2017-2022)



List Of Figures

LIST OF FIGURES

Figure 1. Developmental and Epileptic Encephalopathies (DEE) Segment by Type in 2021 Figure 2. Developmental and Epileptic Encephalopathies (DEE) Segment by Application in 2021 Figure 3. Global Developmental and Epileptic Encephalopathies (DEE) Market Overview: 2021 Figure 4. Key Caveats Figure 5. Global Developmental and Epileptic Encephalopathies (DEE) Market Size: 2021 VS 2028 (US\$, Mn) Figure 6. Global Developmental and Epileptic Encephalopathies (DEE) Revenue, 2017-2028 (US\$, Mn) Figure 7. The Top 3 and 5 Players Market Share by Developmental and Epileptic Encephalopathies (DEE) Revenue in 2021 Figure 8. By Type - Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 9. By Application - Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 10. By Region - Global Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 11. By Country - North America Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 12. US Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 13. Canada Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 14. Mexico Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 15. By Country - Europe Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 16. Germany Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 17. France Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 18. U.K. Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028



Figure 19. Italy Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 20. Russia Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 21. Nordic Countries Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 22. Benelux Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 23. By Region - Asia Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 24. China Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 25. Japan Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 26. South Korea Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 27. Southeast Asia Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 28. India Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 29. By Country - South America Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 30. Brazil Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 31. Argentina Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 32. By Country - Middle East & Africa Developmental and Epileptic Encephalopathies (DEE) Revenue Market Share, 2017-2028 Figure 33. Turkey Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 34. Israel Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 35. Saudi Arabia Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 36. UAE Developmental and Epileptic Encephalopathies (DEE) Revenue, (US\$, Mn), 2017-2028 Figure 37. Biocodex Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 38. Bio-Pharm Solutions Developmental and Epileptic Encephalopathies (DEE)



Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 39. Eisai Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 40. GlaxoSmithKline Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 41. Greenwich Biosciences Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 42. Janssen Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 43. Lundbeck Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 44. Mylan Pharmaceuticals Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 45. PTC Therapeutics Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 46. Roche Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 47. Takeda Pharmaceutical Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 48. Zogenix Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 49. Zynerba Pharma Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022) Figure 50. Ovid Therapeutics Developmental and Epileptic Encephalopathies (DEE) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



I would like to order

Product name: Developmental and Epileptic Encephalopathies (DEE) Market, Global Outlook and Forecast 2022-2028

Product link: https://marketpublishers.com/r/D5A63309EDA3EN.html

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/D5A63309EDA3EN.html</u>